WNDM has been conducting extended research studies on its existing products to seek out these types of advantages. It was recently observed at the University of Colorado and presented at a key worldwide symposium that WNDM's own CellerateRx has been shown to possibly influence biological factors important to wound healing beyond the obvious maintenance of the wound environment.

Divisions of major pharmaceutical companies have long recognized this and position themselves to work with startups to be able to capture emerging technologies that are the best-of-the-best. WNDM is following the lead of these industry leaders and through the BioPharma Division is positioned to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology, Genetic Engineering and Cancer Treatment markets. The recent acquisition of Resorbable Orthopedics LLC with its patented technologies, including a resorbable bone wax and a delivery system for orthopedic bone void fillers, was WNDM's first step to extend its product reach and incubator philosophy beyond Wound Care Innovation and its patented, activated form of collagen found in CellerateRX(R) products. Now, BioPharma Management Technologies is actively seeking additional partners with next generation technologies to add to our portfolio.

We encourage researchers, other companies and Universities to contact us with potential opportunities. For more details, potential Technology and Development Partners are urged to log onto our website at the division's page: http://www.woundmanagementtechnologies.com/wmt-research-and-marketing-collaboration.php . Follow the link named "Licensing Opportunities" to contact our research and development department for consideration.

For Wound Management Technologies Shareholder Information please call Ronnie Ambrose at 954-357-0614.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene (CELG) http://www.celgene.com, Geron (GERN) http://www.geron.com, and Human Genome Sciences (HGSI) http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com or call our shareholder information department at 954-357-0614.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

SOURCE Wound Management Technologies, Inc.

http://www.woundmanagementtechnologies.com

The study suggests that activated collagen (CellerateRx) alone was a potent inducer of IL-6 and the neutrophil chemo-attractant, IL-8, which are important for the acute response to injury and bacterial infection. The study showed that treatment of diabetic ulcers with activated collagen (CellerateRx) and standard therapy significantly accelerated wound healing compared to standard therapy alone. As well, activated collagen (CellerateRx) significantly increased spontaneous (unstimulated) levels of IL-8, IL-6, and IL-10. These results suggest that CellerateRx enhances wound healing, and a possible mechanism involves specific modulation of the cytokine response in bacteria-containing wounds.

Briefly, this groundbreaking research suggests:

    --  Treatment of diabetic ulcers with activated collagen (CellerateRx) and
        standard therapy significantly accelerated wound healing compared to
        standard therapy alone

    --  Activated collagen (CellerateRx) significantly  increased spontaneous
        (unstimulated) levels of IL-8, IL-6, and IL-10

    --  A biphasic activated collagen (CellerateRx) effect on TNF(alpha) and
        IL-1(beta) was shown

"This is a very exciting study for us," stated Cathy Bradshaw, President of Wound Care Innovations. "Dr. Shapiro is a leading authority with worldwide recognition and has published extensively on this subject. These results suggest a scientifically rational mode of action which addresses the results clinicians have seen with CellerateRx."

CellerateRx is FDA cleared for use on acute and chronic wounds which include but are not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and 1st and 2nd degree burns.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is leveraging its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering. WNDM also believes it is positioned to develop its technology in Cancer Treatment. For more information on the Company please visit www.woundmanagementtechnologies.com or call our shareholder information department at 1817 820 7080.

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

    For Further Information:
    Product Information                   Shareholder Relations
    Cathy Bradshaw                        Ronnie Ambrose
    President                             954-357-0614
    954-357-0614

SOURCE Wound Management Technologies, Inc.

http://www.woundmanagementtechnologies.com

Under the terms of the transaction, WMT will acquire Medical Office Software, Inc., Secure eHealth, LLC, and the Veriscrip technology from VirtualHealth Technologies.

Deal Type    Acquisition
Sub-Category Asset Purchase
Deal Status  Announced: 2009-11-05

Deal Participants

Target (Company)   VirtualHealth Technologies, Inc. - Healthcare Assets
Acquirer (Company) Wound Management Technologies, Inc.
Vendor (Company)   VirtualHealth Technologies, Inc.

Deal Rationale

The acquisition fits well with WMT's domestic plans to leverage its existing infrastructure to develop opportunities within the Healthcare market, and focus on the US government healthcare technology initiative. The acquisition will enable WMT to expand its product distribution throughout various medical facilities.

Deal Type    Partnership
Sub-Category Licensing Agreement
Deal Status  Announced: 2009-10-12

Deal Participants

Partner 1 (Company) Secure eHealth, LLC
Partner 2 (Company) VirtualHealth Technologies, Inc.
Partner 3 (Company) Wound Care Innovations, LLC
Partner 4 (Company) Wound Management Technologies, Inc.